Erbitux Sales Growth Will Bounce Back, Says Merck KGaA
This article was originally published in The Pink Sheet Daily
Executive Summary
Later-than-expected tenders in Europe and emerging clinical data are expected to allow sales of best-seller Erbitux to start growing again after an unexpected first-quarter decline, as the German company starts late-stage studies with PD-L1 inhibitor avelumab in its collaboration with Pfizer.